Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986401 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00986401: Completed Phase 1 study, sponsored by Allergan.
NCT00986401 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00986401, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
Primary Outcome
Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.
Interventions
- DRUG Trospium Chloride (Sanctura XR®)
- DRUG Metformin hydrochloride (Glucophage®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2009-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00986401 record still lists
NCT00986401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which Trospium Chloride (Sanctura XR®) is the first listed.
NCT00986401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00986401 about?
NCT00986401 is a clinical study titled "Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects". The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
What is the current status of trial NCT00986401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2009-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00986401?
The interventions under investigation include: Trospium Chloride (Sanctura XR®) (DRUG), Metformin hydrochloride (Glucophage®) (DRUG).
Who is sponsoring clinical trial NCT00986401?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00986401's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia